Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Runimotamab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Participants will be assigned sequentially to escalating doses of runimotamab up to the maximum tolerated dose (MTD). |
| Dose Expansion | EXPERIMENTAL | Participants will receive runimotamab based on the MTD or maximum allowed dose (MAD) identified during dose escalation. |
| Name | Type | Description |
|---|---|---|
| Runimotamab | DRUG | Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met. |
| Trastuzumab | DRUG | Trastuzumab will be administered via IV infusion |
| Tocilizumab | DRUG | Participants will receive IV tocilizumab if needed |
Inclusion Criteria * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy of at least 12 weeks * Adequate hematologic and end-organ function * Acute, clinically significant treatment-related toxicity from prior therapy must have resolved to Grade \</=1 prior to s...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Runimotamab is an investigational small molecule being studied for the treatment of solid tumors. It is currently in Phase 1 clinical development for patients with locally advanced or metastatic HER2-expressing cancers. The drug is being evaluated in a clinical trial to assess its safety and efficacy in this patient population.
Runimotamab is a monoclonal antibody (a -mab) that targets HER2-expressing cancers. It is being developed to treat solid tumors that express the HER2 receptor. The drug is designed to bind to HER2 on cancer cells, potentially interfering with tumor growth and progression.
Runimotamab is being developed by Roche Holding AG, a multinational healthcare company. Roche is conducting clinical trials to evaluate the drug's safety and efficacy in patients with HER2-expressing solid tumors. The company is responsible for the drug's research, development, and potential future commercialization.
Runimotamab is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is designed to assess the drug's safety, tolerability, and preliminary efficacy in patients with locally advanced or metastatic HER2-expressing cancers.
Runimotamab is being studied in a Phase 1 clinical trial with the identifier NCT03448042. This trial is titled 'A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers' and is currently active but not recruiting. The trial has enrolled 123 participants across multiple countries, including the United States, Australia, and several European and Asian nations.
Runimotamab is a unique investigational drug and no alternative names have been reported. It is being developed by Roche as a monoclonal antibody targeting HER2-expressing solid tumors. As a Phase 1 candidate, it is distinct from other HER2-targeted therapies currently on the market or in development.